Liposomal Bupivacaine for Pain Control After Total Shoulder Arthroplasty

• Status: Completed
• Trial end date: 2019-04-15
• Target enrollment: 0
• Participant gender: All

Summary

This study will compare interscalene nerve block versus liposomal bupivacaine (Exparel) for pain control after total shoulder replacements. Each method will be assessed in terms of post operative pain scores, pain medication consumption, length of stay, complications (nerve injuries, hematomas, cardiac/respiratory events) and rate of readmission due to pain. The aims of this study will be achieved through a randomized controlled trial and cost-effectiveness analysis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johns Hopkins University
• Collaborators: Southern Maryland Orthopaedic & Sports Medicine Center; University of Texas Southwestern Medical Center; William Beaumont Army Medical Center
• Treatments: Bupivacaine

Criteria

Inclusion Criteria:

• Degenerative changes of the shoulder joint (documented by radiographs) in patients planning total joint replacement with one of the study's four fellowship-trained orthopaedic surgeons.

• Patients who require revision surgeries, hemiarthroplasties, or who have chronic pain issues will be included.

Exclusion Criteria:

• Allergy to liposomal bupivacaine

• Contraindications to the interscalene nerve block such as:

• Preexisting neurologic defects

• Local anesthetic allergy

• Coagulopathy

• Contralateral phrenic nerve dysfunction

• Severe chronic obstructive pulmonary disease